Potential bias of preoperative intravitreal anti-VEGF injection for complications of proliferative diabetic retinopathy.
<h4>Purpose</h4>Intravitreal anti-VEGF injection (IVI) is administered before vitrectomy to assist management of proliferative diabetic retinopathy (PDR)-related complications. In the clinical setting, retinal surgeons determine the use of preoperative IVI based on individual criteria. I...
Guardado en:
Autores principales: | Kei Takayama, Hideaki Someya, Hiroshi Yokoyama, Takeshi Kimura, Yoshihiro Takamura, Masakazu Morioka, Hiroto Terasaki, Tetsuo Ueda, Nahoko Ogata, Shigehiko Kitano, Maki Tashiro, Taiji Sakamoto, Masaru Takeuchi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/eb6c180c79794c898f39cfa4ae99e127 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Effectiveness of prophylactic intravitreal bevacizumab injection to proliferative diabetic retinopathy patients with elevated preoperative intraocular VEGF in preventing complications after vitrectomy
por: Tsubota K, et al.
Publicado: (2019) -
Incidence of endophthalmitis after intravitreal injection of an anti-VEGF agent with or without topical antibiotics
por: Masakazu Morioka, et al.
Publicado: (2020) -
Is Chronic Kidney Disease Affecting the Postoperative Complications of Vitrectomy for Proliferative Diabetic Retinopathy?
por: Yusuke Kameda, et al.
Publicado: (2021) -
LOCAL AND SYSTEMIC VEGF-А PRODUCTION IN COMPLICATED PROLIFERATIVE DIABETIC RETINOPATHY
por: V. V. Neroev, et al.
Publicado: (2016) -
Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration
por: Mariko Yamashita, et al.
Publicado: (2018)